ÂÜÀòÂÒÂ×

Barbara Duncan serves as a Board Member at several organizations, including Convergent Therapeutics, Inc., Halozyme, Inc., and Atea Pharmaceuticals, Inc. Additionally, Barbara held the position of Chairperson at Fusion Pharmaceuticals until June 2024 and was a Board Member at Versanis Bio, Adaptimmune, Jounce Therapeutics, Inc., ObsEva SA, Aevi Genomics Medicine, and Innoviva, Inc. Academic qualifications include an MBA from The Wharton School and a BS in Accounting from Louisiana State University.